Latest News

Germany to pump €1bn into breakthrough innovation

German Research Minister Anja Karliczek and Economics Minister Peter Altmaier make a joint statement on the founding of the Agency for Jump Innovations following the meeting of the Federal Cabinet. © BMBF / Hans-Joachim Rickel


by tg

Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be funded with roughly €1bn over 10 years.

The move is intented to keep value creation in Germany.  The idea for such an agency is lent from the US agency DARPA (Defense Advanced Research Projects Agency), which was founded by President Dwight D. Eisenhower in the 1950ies to support commercialisation of groundbreaking inventions such as the Internet, GPS or driverless vehicles. Besides Germany, Sweden and Switzerland have already established innovation agencies for non-military purposes. 

The German agency is set to start next year. According to Germany’s minister for economics, Peter Altmaier, a first call will seek for 3 to 4 promising artificial intelligence projects.

Sanofi acquires therapeutic acne vaccine

Privately-owned Origrimm, based in Vienna, develops a vaccine-based immunotherapy against acne. ORI-001 is potentially the first-in-class vaccine...

Pfizer licences Paxlovid to poor countries

Under a contract with the Medicines Patent Pool, Pfizer Inc will waive any royalites for generic makers in 95 poor countries helping to improve...

Stock market boom: Two biotechs go public

After Evotec’s IPO, two more European companies have gone public: IO Biotech raised US$100m in its IPO on Nasdaq Global Market, selling 7.15 million...

Novartis AG executes licence option with Molecular Partners

Further results from the randomized, placebo-controlled Phase IIa EMPATHY trial in acute COVID-19 ambulatory patients suggest that Molecular...

Novartis inks US-$1.3bn deal with Dunad Therapeutics

British start-up company Dunad Therapeutics has signed a collaboration and license agreement with Novartis AG to generate orally bioavailable...

Santhera finds Chinese marketing partner for vamorolone

Under this agreement, Sperogenix will in-license vamorolone for rare disease indications for a total consideration of up to US-$124m, including...

Recordati bags EUSA to strengthen rare disease franchise

EUSA Pharma, which focuses on rare and niche oncology diseases, was founded in 2015. The company has a portfolio of four niche oncology products,...